#### 7.8.2.4 CSP-4 Study Phase Evaluability (CWE) 01054

Components: &lt;Identifier (ST)> ^ &lt;Text (ST)> ^ &lt;Name of Coding System (ID)> ^ &lt;Alternate Identifier (ST)> ^ &lt;Alternate Text (ST)> ^ &lt;Name of Alternate Coding System (ID)> ^ &lt;Coding System Version ID (ST)> ^ &lt;Alternate Coding System Version ID (ST)> ^ &lt;Original Text (ST)> ^ &lt;Second Alternate Identifier (ST)> ^ &lt;Second Alternate Text (ST)> ^ &lt;Name of Second Alternate Coding System (ID)> ^ &lt;Second Alternate Coding System Version ID (ST)> ^ &lt;Coding System OID (ST)> ^ &lt;Value Set OID (ST)> ^ &lt;Value Set Version ID (DTM)> ^ &lt;Alternate Coding System OID (ST)> ^ &lt;Alternate Value Set OID (ST)> ^ &lt;Alternate Value Set Version ID (DTM)> ^ &lt;Second Alternate Coding System OID (ST)> ^ &lt;Second Alternate Value Set OID (ST)> ^ &lt;Second Alternate Value Set Version ID (DTM)>

Definition: This field contains the disposition of the patientâ€™s data for this phase interval for quality control and data analysis purposes. The set of codes will vary across clinical trials. An example answer set: **Complete, Adverse Events Only, Outcome Only, None, Unknown**. Refer to Table 0588 - Study Phase Evaluability in Chapter 2C for valid values.
